WO2021222534A1 - Compounds and methods for prevention and treatment of coronavirus infections - Google Patents

Compounds and methods for prevention and treatment of coronavirus infections Download PDF

Info

Publication number
WO2021222534A1
WO2021222534A1 PCT/US2021/029840 US2021029840W WO2021222534A1 WO 2021222534 A1 WO2021222534 A1 WO 2021222534A1 US 2021029840 W US2021029840 W US 2021029840W WO 2021222534 A1 WO2021222534 A1 WO 2021222534A1
Authority
WO
WIPO (PCT)
Prior art keywords
cov
themethodofclaim
thecomposition
sars
whereinthecoronavirusissars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/029840
Other languages
English (en)
French (fr)
Inventor
Yeh B. WU
Jir-Mehng Lo
Cheng Huang
Hui-Ju Liang
Pei-Hsin Lin
Hao Chiang
Wei-Chung CHIOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arjil Biotech Holding Co Ltd
Original Assignee
Arjil Biotech Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arjil Biotech Holding Co Ltd filed Critical Arjil Biotech Holding Co Ltd
Priority to JP2022566726A priority Critical patent/JP7805010B2/ja
Priority to EP21795939.4A priority patent/EP4142713A1/en
Priority to AU2021264554A priority patent/AU2021264554A1/en
Priority to CN202180046668.8A priority patent/CN116568295B/zh
Publication of WO2021222534A1 publication Critical patent/WO2021222534A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention provides some anti-coronaviral compounds and the method and composition/pharmaceutical composition for prevention and treatment of coronavirus infections, particularly the disease caused by SARS-COV-2.
  • SARS severe acute respiratory syndrome
  • WHO World Health Organization
  • SARS-COV-2 is a novel coronavirus that spreads rapidly since its identification in patients with severe pneumonia in Wuhan, China (named as COVID-19), has been reported in 25 countries, with nearly 72000 laboratory-confirmed cases and a death toll of 1775worldwideasofFebruary17 th ,2020(Coronavirusdisease2019(Covid-19)Situation Report 28,2020;Li& DeClercq,2020).Devastatingly,nodrugorvaccinehasyetbeen approvedtotreathumancoronaviruses(Li& DeClercq,2020).Concerningthecurrent outbreakofSARS-CoV-2andthetherapeuticexperienceofSARSandMERS(anotherb coronavirus),manystudiesextensivelyinvestigatethepossibilityofusingtheexisting
  • SARS-CoV-2 hasbeencharacterizedasanenveloped,positive- sense,single-strandedRNA b coronavirus,similartoSARSandMERS(Li& DeClercq, 2020).Consistentwiththecharacteristicsofcoronaviruses,SARS-CoV-2genomeencodes structuralproteins(e.g.,spikeglycoproteins),nonstructuralproteins(e.g.,3CLpro,PLpro, helicase,RNA-dependentRNA polymerase),andaccessoryproteins.Regardingtheavailable genomicsequenceofSARS-COV-2,SARSandMERS,ahigh-levelconservationofthe proteolyticsitesandproteolyticenzymeswasfound,whencerepurposingSARSandMERS proteaseinhibitorsfortreatmentofSARS-COV-2isworthconsidering(Liuetal.,2020).As 3CLproplaysapivotalroleinSARS,itisreasonable
  • thepresentinvention provides a composition/pharmaceuticalcompositionforpreventingand/ortreatingacoronavirus infection,particularlySARS-COV-2comprisingatherapeuticallyeffectiveamountofanyof thecompoundsdisclosedhereinorpharmaceuticallyacceptablethereof,oritsmixture,in combinationofapharmaceuticallyacceptablecarrier.
  • thecomposition/pharmaceuticalcompositionaccordingtothe invention maycompriseatleastoneadditionalanti-viraltherapeuticagent.
  • thepresentinvention providesauseofanyofthecompounds disclosedhereinorpharmaceuticallyacceptablesalts,oritsmixtureformanufacturinga medicamentforpreventingand/ortreatingacoronavirusinfection,particularlySARS-COV- 2 [0013] Itistobeunderstoodthatboththeforegoinggeneraldescriptionandthe followingdetaileddescriptionare exemplaryandexplanatoryonlyandarenotrestrictiveof theinvention.
  • Thepresentinvention providesamethodforpreventingand/ortreatinga coronavirusinfection,particularlySARS-COV-2comprisingadministeringtoasubjectin needthereofacompoundorpharmaceuticallyacceptablesaltthereof,oritsmixture,inwhich thecompoundisselectedfrom thegroupconsistingof:
  • Thepresentinvention alsoprovidesacomposition/pharmaceuticalcomposition forpreventingand/ortreatingacoronavirusinfection,particularlySARS-COV-2infection, whichcomprisesatherapeuticallyeffectiveamountofacompoundasdisclosedhereinor mixturethereofandapharmaceuticallyacceptablecarrier. [0029] Inoneembodiment,thecompoundis
  • the compound of formula (I) may be:
  • coronavirus referstoaCoronaviruseinthesubfamily Orthocoronavirinae,thefamilyCoronaviridae,orderNidovirales,andrealm Riboviria, whichisenvelopedviruseswithapositive-sensesingle-strandedRNA genomeanda nucleocapsideofhelicalsymmetry.Theyhavecharacteristicclub-shapedspikesthatproject from theirsurface,whichinelectronmicrographscreateanimagepronouncedofthesolar coronafrom whichtheirnamederives.Coronavirusescausediseasesinmammalsandbirds, includinghumans.Inhumans,coronavirusescauserespiratorytractinfections, including commoncold,severeacuterespiratorysyndrome(SARS),MiddleEastrespiratorysyndrome (MERS),andSARS
  • cysteprotease referstothiolproteases,areenzymes thatdegradeproteins,sharingacommoncatalyticmechanism thatinvolvesanucleophilic cysteinethiolinacatalytictriadorduad.
  • Oneexampleofcysteineproteaseinavirusis 3CLproinSARS-COV-2.
  • Theterm “treat,” “treating”or “treatment”asusedherein referstotheapplication oradministrationofacompositionincludingoneormoreactiveagentstoasubjectafflicted withadisease,asymptom orconditionsofthedisease,oraprogressionofthedisease,with thepurposetocure,heal,alleviate,relieve,alter,remedy,ameliorate,improve,oraffectthe disease,thesymptomsorconditionsofthedisease,thedisabilitiesinducedbythedisease,or theprogressionofthedisease.
  • Theterm “prevent,” “prevention”or “preventing”asusedherein referstothe preventionoftherecurrence,onset,ordevelopmentofavirusinfection,oneormore symptomsthereof,orarespiratoryconditionassociatedwith,potentiatedby,orpotentiatinga coronavirusinfectioninasubject.
  • Theterm “subject”asusedhereinin includes humanornon-humananimals,suchas companionanimals(e.g.dogs,cats,etc.),farm animals(e.g.cattle,sheep,pigs,horses,etc.), orexperimentalanimals(e.g.rats,mice,guineapigs,etc.).
  • Theterm “therapeuticallyeffectiveamount”asusedherein referstoanamountof apharmaceuticalagentwhich,ascomparedtoacorrespondingsubjectwhohasnotreceived suchamount,resultsinaneffectintreatment,healing,prevention,orameliorationofa disease,disorder,orsideeffect,oradecreaseintherateofadvancementofadiseaseor disorder.
  • Theterm alsoincludeswithinitsscopeamountseffectivetoenhancenormal physiologicalfunction.
  • thetherapeuticallyeffectiveamountofthecompound is formulatedasapharmaceuticalcompositionforadministration.
  • theinvention furtherprovidesapharmaceuticalcompositioncomprisingatherapeuticallyeffectiveamount ofanyoritsmixtureofthesecompoundsdisclosedherein,andoneormorepharmaceutically acceptablecarriers.
  • Forthepurposeofdeliveryandabsorption atherapeuticallyeffectiveamountof theactiveingredientaccordingtothepresentinventionmaybeformulatedintoa pharmaceuticalcompositioninasuitableform withapharmaceuticallyacceptablecarrier.
  • thepharmaceuticalcompositionofthepresent invention comprisespreferablyfrom 0.1% to100% inweightofthetotalweightoftheactive ingredient.
  • Theterm "pharmaceuticallyacceptablecarrier”usedherein referstoacarrier(s), diluent(s)orexcipient(s)thatisacceptable,inthesenseofbeingcompatiblewiththeother ingredientsoftheformulationandnotdeleterioustothesubjecttobeadministeredwiththe pharmaceuticalcomposition.
  • Someexamplesofappropriateexcipientsin includelactose,dextrose,sucrose, sorbose,mannose,starch,Arabicgum,calcium phosphate,alginates,tragacanthgum,gelatin, calcium silicate,microcrystallinecellulose,polyvinylpyrrolidone,cellulose,sterilizedwater, syrup,andmethylcellulose
  • Thecompositionofthepresentinvention canprovidetheeffectofrapid, continued,ordelayedreleaseoftheactiveingredientafteradministrationtothepatient.
  • thepharmaceuticalcomposition maybeadaptedfor administrationbyanyappropriateroute,includingbutnotlimitedtooral,rectal,nasal, topical,vaginal,orparenteralroute(suchasintramuscular,intravenous,subcutaneous,and intraperitoneal),transdermal,suppository,andintranasalmethods.
  • thepharmaceuticalcomposition is formulatedfororaladministration.Suchformulationsmaybepreparedbyanymethodknown intheartofpharmacy.Accordingtothepresentinvention,theform ofsaidcompositionmay betablets,pills,powder,lozenges,packets,troches,elixers,suspensions,lotions,solutions, syrups,softandhardgelatincapsules,suppositories,sterilizedinjectionfluid,andpackaged powder.
  • themethodandcomposition/pharmaceuticalcomposition are effectiveintreatingavirusinfectionthroughaninhibitionofacysteineproteaseinavirus, particularlyanRNA-dependentvirus.
  • theinvention alsoprovidesamethodand composition/pharmaceuticalcompositionfortreatmentand/orpreventionofavirusinfection throughinhibitionofacysteineproteaseinavirus,comprisingusingthecompounds disclosedhereinorpharmaceuticallyacceptablesaltthereof.
  • Exemplifiedviruseswhichareresponsivein include,withoutlimitation, a coronavirus,andaHIV.Preferably,theviralinfectionisacoronavirus.Morepreferably,the viralinfectionisaSARS,MERSandSARS-COV-2.
  • thepresentinvention providesamethodfortreatingor preventinganRNA-dependentvirusinfectionthroughinhibitingacysteineproteaseina virus.
  • OneexampleofthevirusisanRNA-dependentvirus suchasSARS,MERSand SARS-COV-2;particularlySARS-COV-2.
  • thepresentinvention provides a composition/pharmaceuticalcompositionfortreatingand/orpreventingavirusinfection throughinhibitingacysteineproteaseinavirus,whichcomprisesanyofthecompounds disclosedherein,pharmaceuticallyacceptablesaltthereof,oritsmixture.
  • the composition/pharmaceuticalcomposition maycompriseatleastoneadditionalanti-viral therapeuticagent.
  • thepresentinvention providesauseofanyofthe compoundsdisclosedhereinformanufacturingamedicamentfortreatingorpreventinga virusinfectionthroughinhibitingacysteineproteaseinavirus.
  • TheIC50valuesofAR100DS1 weregivenin Figure3.AR100DS1 hadanIC50valueof21.31mM inthepresenceof0.125pM SARS-CoV-23CLpro and1.25pM IQFpeptidesubstrate.
  • Giventheabove,alltheexamplecompoundsincludingAR100DS1, AR101DS1,AR101DS2,AR101DS3andAR101DS4 wereconfirmedtohave theinhibitoryeffectonSARS-CoV-23CLprohighlightstheirtherapeutic potentialsagainstSARS-CoV-2,particularlyAR100DS1,AR101DS2andAR101 DS3.
  • Coronaviruses drugdiscoveryandtherapeuticoptions.NaturereviewsDrug discovery,15(5),327.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2021/029840 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections Ceased WO2021222534A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022566726A JP7805010B2 (ja) 2020-05-01 2021-04-29 コロナウイルス感染を予防および処置する化合物および方法
EP21795939.4A EP4142713A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections
AU2021264554A AU2021264554A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections
CN202180046668.8A CN116568295B (zh) 2020-05-01 2021-04-29 改善或治疗冠状病毒感染的化合物及方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018690P 2020-05-01 2020-05-01
US63/018,690 2020-05-01

Publications (1)

Publication Number Publication Date
WO2021222534A1 true WO2021222534A1 (en) 2021-11-04

Family

ID=78292168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/029840 Ceased WO2021222534A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections

Country Status (7)

Country Link
US (1) US12433901B2 (https=)
EP (1) EP4142713A1 (https=)
JP (1) JP7805010B2 (https=)
CN (1) CN116568295B (https=)
AU (1) AU2021264554A1 (https=)
TW (1) TW202206080A (https=)
WO (1) WO2021222534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535714A (ja) * 2020-07-23 2023-08-21 アージル・バイオテック・ホールディング・カンパニー・リミテッド ウイルス感染を阻害するための方法および組成物
US20240408055A1 (en) * 2021-10-21 2024-12-12 Peking University Shenzhen Graduate School Use of anisomelic acid in preparation of pharmaceutical composition for inhibiting infection and replication of sars-cov-2 and variants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148504A1 (en) * 2002-11-29 2005-07-07 Nobuhiko Katunuma Cysteine protease inhibitor
US20100210869A1 (en) * 2009-02-13 2010-08-19 Kaohsiung Medical University Ethanol extract of antrodia camphorata for inducing apoptosis and preparation method thereof
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
US20170226150A1 (en) * 2011-01-26 2017-08-10 Kaohsiung Medical University Triterpenoid composition of antrodia cinnamomea, preparation and analysis method thereof
US20200268771A1 (en) * 2019-02-25 2020-08-27 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919665B2 (en) 2009-02-17 2011-04-05 Conocophillips Company Mercury removal from hydrocarbons
FI126047B (en) * 2012-08-28 2016-06-15 John Eriksson Pharmaceutical compositions of anisomelic acid and their use
TWI453026B (zh) * 2013-05-14 2014-09-21 Jenisa Biotechnology Corp Ltd 魚針草萃取物及其純化物抗流感病毒之用途
US9645651B2 (en) 2013-09-24 2017-05-09 Microsoft Technology Licensing, Llc Presentation of a control interface on a touch-enabled device based on a motion or absence thereof
WO2021202982A1 (en) * 2020-04-03 2021-10-07 Turtle Bear Holdings, Llc Compositions and methods for modulating inflammatory response
CN113521060B (zh) * 2020-04-17 2022-12-06 北京大学深圳研究生院 鱼针草内酯抗新型冠状病毒的用途
TW202200175A (zh) * 2020-04-28 2022-01-01 浩峰生物科技股份有限公司 牛樟芝萃取物(Ant-Ex)減少血管收縮素轉換酶2(ACE-2)蛋白質表現

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148504A1 (en) * 2002-11-29 2005-07-07 Nobuhiko Katunuma Cysteine protease inhibitor
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
US20100210869A1 (en) * 2009-02-13 2010-08-19 Kaohsiung Medical University Ethanol extract of antrodia camphorata for inducing apoptosis and preparation method thereof
US20170226150A1 (en) * 2011-01-26 2017-08-10 Kaohsiung Medical University Triterpenoid composition of antrodia cinnamomea, preparation and analysis method thereof
US20200268771A1 (en) * 2019-02-25 2020-08-27 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WU CANRONG, LIU YANG, YANG YUEYING, ZHANG PENG, ZHONG WU, WANG YALI, WANG QIQI, XU YANG, LI MINGXUE, LI XINGZHOU, ZHENG MENGZHU, C: "Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods", ACTA PHARMACEUTICA SINICA B, vol. 10, no. 5, 1 May 2020 (2020-05-01), pages 766 - 788, XP055856728, ISSN: 2211-3835, DOI: 10.1016/j.apsb.2020.02.008 *
YANG PO-SHENG, LIN PO-YEN, CHANG CHAO-CHIEN, YU MENG-CHE, YEN TING-LIN, LAN CHANG-CHOU, JAYAKUMAR THANASEKARAN, YANG CHIH-HAO: "Antrodia camphorata Potentiates Neuroprotection against Cerebral Ischemia in Rats via Downregulation of iNOS/HO-1/Bax and Activated Caspase-3 and Inhibition of Hydroxyl Radical Formation", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, OXFORD UNIVERSITY PRESS, US, vol. 2015, 25 August 2015 (2015-08-25), US , pages 1 - 8, XP055869360, ISSN: 1741-427X, DOI: 10.1155/2015/232789 *

Also Published As

Publication number Publication date
JP7805010B2 (ja) 2026-01-23
EP4142713A1 (en) 2023-03-08
US12433901B2 (en) 2025-10-07
US20210338690A1 (en) 2021-11-04
AU2021264554A1 (en) 2023-01-05
JP2023524274A (ja) 2023-06-09
TW202206080A (zh) 2022-02-16
CN116568295A (zh) 2023-08-08
CN116568295B (zh) 2026-02-13

Similar Documents

Publication Publication Date Title
US20230148179A1 (en) SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF
EP4142713A1 (en) Compounds and methods for prevention and treatment of coronavirus infections
Wang et al. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy
JP2023515227A (ja) 抗コロナウイルスにおけるジスルフィラムの使用
JP7584161B2 (ja) Ｎ－置換ピリジルベンズイソセラゾロン化合物の使用
US20210379058A1 (en) Arylamide Compounds For Treatment And Prevention Of Viral Infections
EP4153158A1 (en) Use of psychotropic drugs for the treatment of coronavirus infections
US11963955B2 (en) Compositions for and methods of inhibiting SARS-CoV2 infection
Chakraborty et al. NL-63: A better surrogate virus for studying SARS-CoV-2
WO2021196666A1 (zh) 高三尖杉酯碱在制备人体β-冠状病毒复制抑制剂中的应用
BRPI0413585A (pt) composto ou sal farmaceuticamente aceitável ou um precursor hidrolisável in vivo deste, uso de um composto ou um sal deste farmaceuticamente aceitável, métodos para o tratamento de cáncer, e de infecções associadas com cáncer, composição farmacêutica, e, processo para preparação e uso de um composto ou um sal farmacêuticamente aceitável ou um precursor hidrolisável in vivo
Wang et al. SARS-CoV-2: Structure
TW202144380A (zh) 用於治療冠狀病毒感染之化合物
CN114504575A (zh) 泮托拉唑在制备抑制冠状病毒的产品及抗冠状病毒感染药物中的应用
RU2829731C1 (ru) Применение дисульфирама при резистентности коронавируса
Setayesh-Mehr et al. Dentistry pathways of coronaviruses transmission: a review
CN119174746B (zh) 二苯甲酰甲烷用于抑制冠状病毒及治疗由其引起的相关疾病的用途
US20230002774A1 (en) Methods and compostions for inhibiting coronaviral replication
TWI917417B (zh) 治療病毒感染之方法及組合物
Zhu et al. The Tetrahydroisoquinoline Derivative SP9 Exhibits Antiviral Activity Against PEDV and MHV
US11045519B2 (en) Arginine-rich polypeptide compositions and methods of using same
Gupta et al. A comprehensive review on cervical cancer; HPV infection to Prevention
UA18023U (en) Method for sclerotherapy of ovarian cysts
CN116003508A (zh) 一种含氰基的硒代丁内酰胺化合物及其制备方法和用途
Prusty et al. COVID-19 Pandemic: Epidemiology, diagnosis, and treatment knowledge

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21795939

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022566726

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021795939

Country of ref document: EP

Effective date: 20221201

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202180046668.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2021264554

Country of ref document: AU

Date of ref document: 20210429

Kind code of ref document: A